NRX-1074 is a novel modulator of the NMDA receptor. It is a second-generation follow-on to Naurex’s lead compound, GLYX-13. NRX-1074 is similar to GLYX-13, but is orally active and significantly more potent. The drug is in Phase 2 clinical development for the treatment of major depressive disorder (MDD).

The objectives of the Phase 2 study now underway are to evaluate the safety and efficacy of a single dose of NRX-1074 administered to subjects with MDD. This Phase 2 study follows successful completion of a randomized, placebo-controlled Phase 1 study that assessed the safety of the compound in normal volunteers. In this study, NRX-1074 was well-tolerated, with no signs of the schizophrenia-like psychotomimetic effects associated with NMDA receptor antagonists, such as ketamine.

NRX-1074 has mechanistic activity similar to that of GLYX-13. In multiple nonclinical studies, NRX-1074 has shown rapid onset and long duration of antidepressant-like effects with good safety and no signs of CNS-related side effects.